Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898576 | 0.85 | KMT2A (0.55) | MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17898591 | 0.85 | MAPT (0.55) | MAPTL3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL17898566 | 0.83 | MAPT (0.53) | MAPTL3MBTL1LMNAALDH1A1MAPK1 | |
| SCHEMBL19490486 | 0.82 | MAPT (0.48) | MAPTSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL17898575 | 0.81 | ALOX5 (0.57) | MAPTL3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11731876 | 0.80 | VCAM1 (0.65) | MAPTL3MBTL1SMN1; SMN2VCAM1LMNA | |
| SCHEMBL17898569 | 0.78 | MAPT (0.55) | MAPTSMN1; SMN2LMNAALDH1A1MAPK1 | |
| SCHEMBL17902701 | 0.76 | KMT2A (0.50) | MAPTSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL17902702 | 0.75 | MAPT (0.59) | MAPTSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL19077934 | 0.75 | NPC1 (0.55) | MAPTSMN1; SMN2LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | MAPT 4620/4885L3MBTL1 2809/4885SMN1; SMN2 4625/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | MAPT 4620/4885L3MBTL1 2809/4885SMN1; SMN2 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.